Mayo Clinic proceedings
-
To determine variables associated with difficult clinical encounters. ⋯ Most variables associated with physician impressions of difficult encounters were visit-related, suggesting some patient-related factors (eg, prior substance abuse, translator requirement) may be less relevant in pain patients. Future research should evaluate interventions designed to decrease the difficulty of encounters and determine their effect on patients and physicians.
-
Mayo Clinic proceedings · Jan 2025
Association of Informal Caregiving and Menopause Symptoms in Midlife Women: A Cross-Sectional Study.
To assess the association between caregiving and menopause symptom burden in midlife women. ⋯ This study identified a positive association between caregiving hours and menopause symptom burden. Given the aging US population and likely resultant increases in caregiving burden, there is a critical need to address menopause symptoms and to provide support for midlife women in caregiving roles.
-
Mayo Clinic proceedings · Jan 2025
Prevalence and Incidence of Type 1 Brugada Pattern: A 30-Year Experience at Mayo Clinic.
To identify the incidence and prevalence of type 1 Brugada pattern at Mayo Clinic during 30 years. ⋯ The incidence of type 1 Brugada pattern at Mayo Clinic has increased during 3 decades. The prevalence of type 1 Brugada pattern in the United States is higher than previously reported. Type 1 Brugada pattern in Black and Hispanic populations is more common than previously suspected.
-
Mayo Clinic proceedings · Jan 2025
Genotype-Guided P2Y12 Inhibitor Monotherapy Within 7 Days of Percutaneous Coronary Intervention in High Bleeding Risk Patients: The CHAMP Trial - A Pilot Study and Safety Assessment.
To test the feasibility and safety of genotype guidance in the selection of P2Y12 monotherapy within 1 week of percutaneous coronary interventions (PCIs) among patients with high bleeding risk (HBR). ⋯ Genotype-guided P2Y12 inhibitor monotherapy within a week of PCI is feasible and likely safe in patients with HBR (CHAMP [Clopidogrel With High Bleeding Risk and Adverse Events With Monotherapy in Patients Undergoing Percutaneous Coronary Interventions]; NCT05223335).